IGMS and MVIR-B Related Headlines
Go Back- Fostrox + Lenvima continues to show promising tumor control in HCC, all patients have now dosed at least two treatment cycles (IGMS) (MVIR)
- Fostrox + Lenvima continues to show promising tumor control in HCC, all patients have now dosed at least two treatment cycles
- Medivir's Partner Tango Therapeutics received FDA clearance to start the TNG348 phase 1/2 clinical study
- Medivir reports promising interim data, including a first complete response in phase 1b/2a HCC study with fostrox in combination with Lenvima
- Medivir to present at the Erik Penser Bank Company Event
- Promising tumor control for fostrox in combination with Lenvima in ongoing phase 2a study in HCC, 15th patient included
IGMS and MVIR-B Related Press Releases
Go Back- Fostrox + Lenvima continues to show promising tumor control in HCC, all patients have now dosed at least two treatment cycles
- Medivir's Partner Tango Therapeutics received FDA clearance to start the TNG348 phase 1/2 clinical study
- Medivir reports promising interim data, including a first complete response in phase 1b/2a HCC study with fostrox in combination with Lenvima
- Medivir to present at the Erik Penser Bank Company Event
- Promising tumor control for fostrox in combination with Lenvima in ongoing phase 2a study in HCC, 15th patient included
